Skip to main content
Oncotarget logoLink to Oncotarget
. 2018 Nov 13;9(89):36048. doi: 10.18632/oncotarget.26373

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy

Toril Holien 1, Kristine Misund 1, Oddrun Elise Olsen 1, Katarzyna Anna Baranowska 1, Glenn Buene 1, Magne Børset 1,2, Anders Waage 1,3, Anders Sundan 1,4
PMCID: PMC6267601  PMID: 30542518

This article has been corrected: The legends for figures 1 and 2 were accidentally switched. The corrected figure legends are given below:

Figure 1: Expression of MYC in myeloma cell lines correlated positively with sensitivity to MYC inhibition. The IC50-values of the MYC inhibitor 10058-F4 calculated from the results shown in Supplementary Figure 2 was compared with A. MYC mRNA values or B. MYC/GAPDH relative protein levels. The slope and R2-values are shown in the plots.

Figure 2: MYC gene copy numbers determine expression of MYC mRNA and protein in myeloma cell lines. In a panel of myeloma cell lines the levels of MYC gene copy numbers as measured by PCR was related to A. MYC mRNA measured using nCounter, and B. MYC protein levels measured using immunoblotting and normalized to GAPDH. The slope and R2-values are shown in the plots.

Original article: Oncotarget. 2015; 6:22698-22705. https://doi.org/10.18632/oncotarget.4245


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES